Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARWR
  • CUSIP: N/A
  • Web: www.arrowheadpharma.com
Capitalization:
  • Market Cap: $265.44 million
  • Outstanding Shares: 74,772,000
Average Prices:
  • 50 Day Moving Avg: $2.49
  • 200 Day Moving Avg: $1.89
  • 52 Week Range: $1.20 - $8.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.38
  • P/E Growth: -1.14
Sales & Book Value:
  • Annual Revenue: $22.73 million
  • Price / Sales: 11.68
  • Book Value: $1.21 per share
  • Price / Book: 2.93
Profitability:
  • EBIDTA: ($47,970,000.00)
  • Net Margins: -201.84%
  • Return on Equity: -46.73%
  • Return on Assets: -34.08%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 3.84%
  • Quick Ratio: 3.84%
Misc:
  • Average Volume: 1.24 million shs.
  • Beta: 1.81
  • Short Ratio: 10.59
 

Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Thursday, August, 3rd. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company earned $9.34 million during the quarter, compared to analysts' expectations of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. View Arrowhead Pharmaceuticals' Earnings History.

When will Arrowhead Pharmaceuticals make its next earnings announcement?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Arrowhead Pharmaceuticals.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $2.00 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

  • Douglass B. Given M.D., Ph.D., Chairman of the Board
  • Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director
  • Kenneth Allen Myszkowski, Chief Financial Officer
  • Bruce D. Given M.D., Chief Operating Officer
  • Patrick O'Brien, General Counsel
  • Michael S. Perry Ph.D., Lead Independent Director
  • Mauro Ferrari Ph.D., Independent Director
  • Edward W. Frykman, Independent Director

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.63%), LMR Partners LLP (0.39%), California Public Employees Retirement System (0.31%), Northern Trust Corp (0.30%), Schwab Charles Investment Management Inc. (0.21%) and Virtu KCG Holdings LLC (0.13%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given, Kenneth Allen Myszkowski and Mauro Ferrari. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including LMR Partners LLP and Virtu KCG Holdings LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.55.


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $2.00 (43.66% downside)

Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/13/2017Chardan CapitalReiterated RatingNeutralMediumView Rating Details
9/15/2017Cantor FitzgeraldReiterated RatingHold$1.00 -> $2.00HighView Rating Details
8/4/2017Jefferies Group LLCReiterated RatingHold$2.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingHold$2.00MediumView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.10)N/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20173($0.15)($0.13)($0.14)
Q4 20173($0.18)($0.10)($0.15)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 20.61%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Source:
DateHeadline
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)
www.americanbankingnews.com - September 20 at 9:22 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William Blair
www.americanbankingnews.com - September 18 at 11:32 PM
americanbankingnews.com logoAnalyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - September 17 at 2:31 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM
finance.yahoo.com logoHere's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
finance.yahoo.com - September 15 at 4:23 PM
americanbankingnews.com logoCantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)
www.americanbankingnews.com - September 15 at 7:28 AM
finance.yahoo.com logoArrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
finance.yahoo.com - September 14 at 4:38 PM
americanbankingnews.com logoZacks: Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Post Quarterly Sales of $7.32 Million
www.americanbankingnews.com - September 14 at 5:22 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 5:06 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - September 13 at 12:34 AM
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:00 AM
finance.yahoo.com logoArrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 11 at 8:58 PM
finance.yahoo.com logoArrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 10:05 PM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 10:10 PM
businesswire.com logoArrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)
www.businesswire.com - September 1 at 9:40 PM
finance.yahoo.com logoArrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
finance.yahoo.com - September 1 at 4:37 PM
americanbankingnews.com logoFY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)
www.americanbankingnews.com - August 28 at 3:38 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - August 27 at 2:26 PM
americanbankingnews.com logo$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter
www.americanbankingnews.com - August 27 at 5:50 AM
americanbankingnews.com logoContrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)
www.americanbankingnews.com - August 19 at 8:44 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 19 at 4:36 AM
americanbankingnews.com logoFinancial Comparison: Arrowhead Pharmaceuticals (ARWR) and Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - August 16 at 4:58 PM
americanbankingnews.com logo$7.98 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter
www.americanbankingnews.com - August 9 at 7:46 AM
finance.yahoo.com logoToday’s Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals
finance.yahoo.com - August 8 at 3:56 PM
americanbankingnews.com logoZacks: Brokerages Expect Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.14 EPS
www.americanbankingnews.com - August 7 at 8:32 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - August 6 at 12:34 AM
seekingalpha.com logoArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 9:24 PM
finance.yahoo.com logoEdited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 4:22 PM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Announces Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM
finance.yahoo.com logoInvestor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 5:29 PM
finance.yahoo.com logoArrowhead Reports Fiscal 2017 Third Quarter Results
finance.yahoo.com - August 3 at 5:29 PM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:20 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earns Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 30 at 3:56 PM
marketwatch.com logoPopular biotech ETF on pace for steepest daily drop in a month - MarketWatch
www.marketwatch.com - July 27 at 4:07 PM
finance.yahoo.com logoArrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
finance.yahoo.com - July 27 at 4:06 PM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 25 at 10:27 AM
americanbankingnews.com logoZacks: Analysts Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Quarterly Sales of $5.29 Million
www.americanbankingnews.com - July 19 at 10:22 AM
americanbankingnews.com logo Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 18 at 12:22 AM
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 4:05 PM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Sees Large Drop in Short Interest
www.americanbankingnews.com - June 29 at 7:13 AM
americanbankingnews.com logoArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 28 at 8:48 AM
americanbankingnews.com logo Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Post Quarterly Sales of $5.29 Million
www.americanbankingnews.com - June 23 at 1:42 PM
americanbankingnews.com logoZacks: Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - June 21 at 10:48 PM
businesswire.com logoArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - June 10 at 3:38 PM
finance.yahoo.com logoArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
finance.yahoo.com - June 9 at 9:00 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 2 at 7:02 PM
americanbankingnews.com logo$5.29 Million in Sales Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter
www.americanbankingnews.com - May 28 at 8:37 AM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 12.3% in May
www.americanbankingnews.com - May 27 at 7:08 AM
americanbankingnews.com logoZacks: Analysts Anticipate Arrowhead Pharmaceuticals Inc (ARWR) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 26 at 4:32 PM
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 3:57 PM

Social

Chart

Arrowhead Pharmaceuticals (ARWR) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff